This ADC presented very high potency against CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma cells in vitro, with IC50 of 3 to 50 pM, while non-expressing CD30 cells were ~1000 times more resistant [196]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.